MediClin AG (XTER:MED) ROCE % : -8.83% (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is MediClin AG ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. MediClin AG's annualized ROCE % for the quarter that ended in Dec. 2023 was -8.83%.

MediClin AG ROCE % Historical Data

The historical data trend for MediClin AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediClin AG ROCE % Chart

MediClin AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

4.07

0.03

1.70

2.89

2.10

MediClin AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															5.63	-0.86	7.77	10.02	-8.83

MediClin AG ROCE % Calculation

MediClin AG's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	15.259	/	( ( (916.112 - 170.843)	+	(880.502 - 171.239) )	/ 2 )
	=	15.259	/	( (745.269	+	709.263)	/ 2 )
	=	15.259	/	727.266
	=	2.10 %

MediClin AG's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-64.096	/	( ( (911.977 - 169.048)	+	(880.502 - 171.239) )	/ 2 )
	=	-64.096	/	( ( 742.929	+	709.263 )	/ 2 )
	=	-64.096	/	726.096
	=	-8.83 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

MediClin AG (XTER:MED) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

MediClin AG ROCE % Related Terms

Thank you for viewing the detailed overview of MediClin AG's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

MediClin AG (XTER:MED) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » MediClin AG (XTER:MED) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MED:Germany MED:Germany

Address

Okenstrasse 27, Offenburg, DEU, 77652

Website

https://www.mediclin.de

MediClin AG is a company engaged in operating hospitals. It is focused on providing services in the areas of neurosciences and psychological sciences as well as orthopedics in Germany. The hospitals are acute-care hospitals providing basic, standard, and specialized care, as well as specialist clinics for medical rehabilitation. The operating segments of the group are Post-acute, Acute and Other activities. It generates majority of the revenue from the Post-acute segment in which the firm offers services in the fields of subsequent nursing treatment and curative treatment. Subsequent nursing treatment starts after acute care treatment and includes all medical measures required to facilitate the healing process and return the patient to a functioning state.